625
Participants
Start Date
March 8, 2021
Primary Completion Date
March 25, 2022
Study Completion Date
January 22, 2026
VLA15
a multivalent recombinant Outer Surface Protein A (OspA) based vaccine candidate
Placebo
PBS (Phosphate Buffered Saline)
Richmond Behavioral Associates, Staten Island
Advantage Clinical Trials, The Bronx
Pfizer Vaccine Research and Development, Pearl River
Synevo Studien Service Labor GmbH c/o Institut für Medizinische Diagnostik, Berlin
Meridian Clinical Research LLC, Binghamton
Rochester Clinical Research, Inc., Rochester
Allegheny Health and Wellness Pavilion, Erie
Liberty Family Practice, Erie
Lockman & Lubell Pediatric Associates, Fort Washington
Velocity Clinical Research, Inc., Cleveland
Clinical Research Institute, Inc., Minneapolis
New England Research Associates, Bridgeport
Stamford Therapeutics Consortium, Stamford
Chase Medical Research, LLC, Waterbury
Pediatric Associates of Conn. PC, Waterbury
Quest Diagnostics, Marlborough
Foundation Pediatrics, East Orange
Med Clinical Research Partners, LLC, Irvington
Hasbro Children's Hospital, Providence
Rhode Island Hospital, Providence
The Miriam Hospital, Providence
Velocity Clinical Research Providence, Warwick
Lead Sponsor
Valneva Austria GmbH
INDUSTRY
Pfizer
INDUSTRY